Effective Pseudomonas aeruginosa Eradication in Cystic Fibrosis: Multicenter Study

Guliyeva A., YILMAZ YEĞİT C., Yanaz M., Kalyoncu M., Selçuk Balcı M., KARABULUT Ş., ...Daha Fazla

Clinical Pediatrics, cilt.64, sa.11, ss.1581-1588, 2025 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 64 Sayı: 11
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1177/00099228251351699
  • Dergi Adı: Clinical Pediatrics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EBSCO Education Source, EMBASE, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.1581-1588
  • Anahtar Kelimeler: cystic fibrosis, eradication, Pseudomonas aeruginosa
  • Marmara Üniversitesi Adresli: Evet

Özet

Background: Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen. Methods: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients. Results: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%). Conclusion: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.